Hims & Hers Health (NYSE:HIMS) Given New $39.00 Price Target at Truist Financial

Hims & Hers Health (NYSE:HIMS) had its price objective upped by equities researchers at Truist Financial from $24.00 to $39.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has a “hold” rating on the stock. Truist Financial’s target price suggests a potential downside of 2.37% from the stock’s current price.

Other equities research analysts have also issued reports about the stock. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. Morgan Stanley downgraded Hims & Hers Health from an “overweight” rating to an “equal weight” rating and boosted their price target for the company from $42.00 to $60.00 in a research note on Tuesday, February 18th. TD Cowen restated a “buy” rating and issued a $28.00 price objective on shares of Hims & Hers Health in a research note on Wednesday, November 20th. BTIG Research assumed coverage on Hims & Hers Health in a report on Tuesday, January 7th. They set a “buy” rating and a $35.00 target price for the company. Finally, Citigroup increased their price target on shares of Hims & Hers Health from $25.00 to $27.00 and gave the stock a “sell” rating in a report on Tuesday. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $34.47.

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $39.95 on Wednesday. The stock has a market capitalization of $8.73 billion, a price-to-earnings ratio of 90.79 and a beta of 1.35. The business has a fifty day moving average price of $35.62 and a 200-day moving average price of $26.25. Hims & Hers Health has a 1-year low of $9.67 and a 1-year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. The firm had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. On average, equities research analysts anticipate that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other news, insider Michael Chi sold 17,303 shares of the stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $48.14, for a total transaction of $832,966.42. Following the transaction, the insider now owns 193,601 shares in the company, valued at $9,319,952.14. This trade represents a 8.20 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Andrew Dudum sold 33,513 shares of Hims & Hers Health stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $33.38, for a total transaction of $1,118,663.94. Following the completion of the sale, the chief executive officer now directly owns 33,502 shares in the company, valued at $1,118,296.76. This represents a 50.01 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,097,578 shares of company stock valued at $38,080,320 in the last ninety days. 17.71% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of HIMS. Crewe Advisors LLC purchased a new stake in Hims & Hers Health during the 4th quarter worth approximately $28,000. Raleigh Capital Management Inc. boosted its stake in shares of Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after acquiring an additional 1,100 shares during the last quarter. Blume Capital Management Inc. boosted its stake in shares of Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after acquiring an additional 600 shares during the last quarter. Smartleaf Asset Management LLC increased its position in shares of Hims & Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock worth $36,000 after purchasing an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC acquired a new position in Hims & Hers Health in the 4th quarter valued at $38,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.